Evolent Health, Inc. Segments Disclosure
| For the Year Ended December 31, | ||||||||||||||||||||
| 2025 | 2024 | 2023 | ||||||||||||||||||
| Revenue | $ | 1,876,229 | $ | 2,554,741 | $ | 1,963,896 | ||||||||||||||
| Less: | ||||||||||||||||||||
Medical expense and device costs (1) | 1,096,794 | 1,813,052 | 1,143,499 | |||||||||||||||||
Cost of revenue excluding medical expense and device costs and other segment items (2) | 376,321 | 369,754 | 358,265 | |||||||||||||||||
Selling, general and administrative expenses excluding other segment items (3) | 251,959 | 211,475 | 267,454 | |||||||||||||||||
| Depreciation and amortization expenses | 115,851 | 118,370 | 123,415 | |||||||||||||||||
| Goodwill impairment | 398,000 | — | — | |||||||||||||||||
| Interest income | (4,190) | (5,544) | (5,256) | |||||||||||||||||
| Interest expense | 57,471 | 24,722 | 54,205 | |||||||||||||||||
| Gain (loss) from equity method investees | (365) | 3,441 | (1,290) | |||||||||||||||||
| Provision from income taxes | (126) | (1,413) | (89,365) | |||||||||||||||||
| Change in tax receivables agreement liability | 804 | 173 | 61,982 | |||||||||||||||||
Other segment items (4) | 163,111 | 114,165 | 193,247 | |||||||||||||||||
| Net loss attributable to common shareholders of Evolent Health, Inc. | $ | (579,401) | $ | (93,454) | $ | (142,260) | ||||||||||||||
| For the Year Ended December 31, | ||||||||||||||||||||
| 2025 | 2024 | 2023 | ||||||||||||||||||
| Stock-based compensation | $ | 36,508 | $ | 35,164 | $ | 38,839 | ||||||||||||||
| Severance costs | 10,147 | 2,877 | 1,505 | |||||||||||||||||
| Transaction-related costs | 5,252 | 2,934 | 15,076 | |||||||||||||||||
| Repositioning costs | — | 10,600 | 35,236 | |||||||||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 25, 2026 | Showing above |
| 2024 | Feb 21, 2025 | |
| 2022 | Feb 24, 2023 | |
| 2021 | Feb 24, 2022 | |
| 2020 | Feb 26, 2021 | |
| 2019 | Mar 2, 2020 | |
| 2018 | Feb 28, 2019 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.